Next Article in Journal
Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
Previous Article in Journal
Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Salmonella Enteritidis Subunit Vaccine Candidate Based on SseB Protein Co-Delivered with Simvastatin as Adjuvant

1
Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou 225009, China
2
Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China
3
Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, MOA, Yangzhou University, Yangzhou 225009, China
4
Joint International Research Laboratory of Agriculture and Agri-Product Safety of the Ministry of Education, Yangzhou University, Yangzhou 225009, China
*
Authors to whom correspondence should be addressed.
Pathogens 2022, 11(4), 443; https://doi.org/10.3390/pathogens11040443
Submission received: 21 March 2022 / Revised: 4 April 2022 / Accepted: 5 April 2022 / Published: 7 April 2022

Abstract

Salmonella enterica serovar Enteritidis (S. Enteritidis) is an important zoonotic pathogen that can lead to diarrhea and systemic infections in humans and mortality in animals. This is a major public health issue worldwide. Safe and effective vaccines are urgently needed to control and prevent Salmonella infection. Subunit vaccines are safe and provide targeted protection against Salmonella spp. Here, we developed and evaluated an S. Enteritidis subunit vaccine candidate, the rHis-SseB adjuvant with simvastatin. We amplified the SseB gene from S. Enteritidis C50041 genomic DNA and expressed the recombinant proteins rHis-SseB and rGST-SseB using the Escherichia coli system. Western blotting confirmed the immunoreactivity of recombinant proteins rHis-SseB and rGST-SseB with antisera against Salmonella Enteritidis C50041. In a mouse model of intramuscular vaccination, co-immunization with rHis-SseB and simvastatin significantly enhanced both the SseB-specific antibody titer in serum (humoral immune response) and splenic lymphocyte proliferation (cellular immune response). Co-immunization with rHis-SseB and simvastatin provided 60% protection against subsequent challenge with the S. Enteritidis C50041 strain and decreased bacterial colonization in the liver and spleen. These findings provide a basis for the development of an S. Enteritidis subunit vaccine.
Keywords: S. Enteritidis; subunit vaccine; SseB; simvastatin; immune response; immune protection S. Enteritidis; subunit vaccine; SseB; simvastatin; immune response; immune protection

Share and Cite

MDPI and ACS Style

Kang, X.; Huang, T.; Shen, H.; Meng, C.; Jiao, X.; Pan, Z. Salmonella Enteritidis Subunit Vaccine Candidate Based on SseB Protein Co-Delivered with Simvastatin as Adjuvant. Pathogens 2022, 11, 443. https://doi.org/10.3390/pathogens11040443

AMA Style

Kang X, Huang T, Shen H, Meng C, Jiao X, Pan Z. Salmonella Enteritidis Subunit Vaccine Candidate Based on SseB Protein Co-Delivered with Simvastatin as Adjuvant. Pathogens. 2022; 11(4):443. https://doi.org/10.3390/pathogens11040443

Chicago/Turabian Style

Kang, Xilong, Tingting Huang, Huanhuan Shen, Chuang Meng, Xinan Jiao, and Zhiming Pan. 2022. "Salmonella Enteritidis Subunit Vaccine Candidate Based on SseB Protein Co-Delivered with Simvastatin as Adjuvant" Pathogens 11, no. 4: 443. https://doi.org/10.3390/pathogens11040443

APA Style

Kang, X., Huang, T., Shen, H., Meng, C., Jiao, X., & Pan, Z. (2022). Salmonella Enteritidis Subunit Vaccine Candidate Based on SseB Protein Co-Delivered with Simvastatin as Adjuvant. Pathogens, 11(4), 443. https://doi.org/10.3390/pathogens11040443

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop